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PMH32
THE IMPACT OF DULOXETINE FOR THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER
ON THE QUALITY OF LIFE IN DEPRESSION
SCALE
Robinson RL, Obenchain RL, Croghan TW
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Duloxetine hydrochloride, a potent and
balanced dual reuptake inhibitor of serotonin and 
norepinephrine, previously has been shown to be safe 
and efﬁcacious among patients with major depressive 
disorder, with efﬁcacy measured by the Hamilton Depres-
sion Scale (HAM-D17). Our analyses show that treat-
ment with duloxetine also has a favorable impact on
quality of life.
METHODS: Adult patients (N = 353) from multiple
centers throughout the United States were included in a
double-blind, placebo- and active comparator-controlled
clinical trial. Patients were randomized to duloxetine 
40mg/day (administered 20mg/BID), duloxetine 80mg/
day (administered 40mg/BID), paroxetine 20mg/day, or
placebo, and followed for eight weeks. The protocol
called for 3 repeated measures on the Quality of Life in
Depression Scale (QLDS). The QLDS is a 34 item patient-
reported, unidimensional, depression-speciﬁc measure,
with lower scores indicating greater quality of life
(increased capacity to satisfy one’s own needs). To make
area-under-the-curve comparisons, mixed-model estima-
tion with random patient slopes and intercepts was used
to singly impute missing values. Sensitivity analyses using
Prediction plus Resampled Residual (PpRR) bootstrap-
ping were used to verify that single imputation had not
biased estimates associated with repeated measurements
on either QLDS or HAM-D17.
RESULTS: Duloxetine 80mg/day consistently produced
the lowest repeated QLDS scores. After adjusting for
baseline differences, both duloxetine 80mg/day and
paroxetine 20mg/day produce signiﬁcantly lower (p =
0.0001) QLDS scores than placebo. But duloxetine 
80mg/day patients reported signiﬁcantly lower (p = 0.002
to 0.01) QLDS scores than paroxetine patients. Similar
signifance levels resulted when using HAM-D17 as the
outcome.
CONCLUSIONS: In an 8-week randomized clinical trial,
duloxetine 80mg/day improved patient-reported scores
on QLDS in a way that is highly consistent with the 
corresponding improvements in HAM-D17 clinical 
measures. As many items from the QLDS and HAM-D17
are correlated, the overlap between quality of life and
mood should be further investigated.
PMH33
QUALITY OF LIFE IN SCHIZOPHRENIA:THE
RELATIONSHIP BETWEEN PARTICIPANT 
SELF-REPORT AND CLINICAL ASSESSMENT
Russo P1, Smith MW2
1The MEDSTAT Group, Inc, Washington, DC, USA; 2VA Palo
Alto Health Care System, Menlo Park, CA, USA
OBJECTIVE: To examine the relationship between self-
reported and clinically assessed quality of life (QoL)
among participants in the U.S. Schizophrenia Care and
Assessment Program (SCAP).
METHODS: Data reﬂect measures obtained at the 12-
month assessment period (n = 908). Clinical instruments
were the Quality of Life Scale (QLS), Montgomery-
Asberg Depression Rating Scale (MADRS), Positive 
and Negative Symptoms Scale (PANSS) and Abnormal
Involuntary Movement Scale (AIMS). Self-report data
were obtained from Life Satisfaction (LifeSat) scale and
Depression scale, component scales of the SCAP Health
Questionnaire. Cross-sectional regression analyses were
conducted.
RESULTS: Correlation between the subjective and objec-
tive scale totals and component items were signiﬁcant in
most instances with magnitudes ranging from 0.2 to 0.6.
Clinical rating of QLS was signiﬁcantly and inversely
impacted by PANSS (p < 0.001) and MADRS (p < 0.001).
Unlike QLS, self-reported LifeSat was impacted by
MADRS (p < 0.001) and not by symptoms (PANSS). The
magnitude of effect of MADRS was 38% greater on
LifeSat than on QLS. Two QLS sub-scales (common
objects and activities [COA] and interpersonal relations
[IPR]) exhibited a signiﬁcant relationship with LifeSat 
(p < 0.01 and p < 0.001, respectively). In the presence of
MADRS, however, signiﬁcance of clinical symptoms and
QLS subscales diminished and R-squared increased. 
Clinically assessed depression exhibited a signiﬁcant rela-
tionship (0.38; p < 0.001) to self-reported depression.
CONCLUSIONS: The relationship of self-report to 
clinical assessment is of particular interest for persons
with schizophrenia given the current climate of partici-
patory treatment planning and outcome milestone
achievement. These ﬁndings demonstrate several impor-
tant points: 1) participant self-reports and clinical assess-
ments exhibit signiﬁcant interrelation for both QoL and
depression; 2) clinical symptoms and side effects are not
important drivers of self-reported QoL; 3) level of depres-
sion is an important factor in patients’ own sense of life
satisfaction; and 4) depression scores exhibit a mediating
effect between psychiatric symptom presentation and 
valuation of quality of life.
PMH34
PSYCHOMETRIC EVALUATION OF THE
MODIFIED STRAIN IN NURSING CARE
ASSESSMENT SCALE
Ciesla G1, Frank L1, Kleinman L1, Brodaty H2, Rupnow M3
1MEDTAP International, Bethesda, MD, USA; 2University of
New South Wales, Sydney, Australia; 3Janssen Pharmaceutica
Products, L.P,Titusville, NJ, USA
OBJECTIVES: The objective of this study was to evalu-
ate the psychometric properties (reliability and validity)
of the Modiﬁed Strain in Nursing Care Assessment Scale
(M-NCAS), a 32-item scale for assessing dementia-related
behaviors and the extent of job burden caused by those
behaviors.
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METHODS: M-NCAS data were collected from nursing
staff ratings of nursing home patients diagnosed with
dementia (N = 281), in a randomized double-blind 
clinical trial comparing risperidone to placebo (RIS-AUS-
5 trial). For each item nurses rated the extent to which
they agree the target patient exhibits the behavior (agree,
partially agree, doubtful/unsure, don’t agree) and the
extent to which the behavior is difﬁcult to cope with (very
easy, easy, difﬁcult, very difﬁcult). Exploratory factor
analyses were performed separately for “agree” and
“cope” scales to determine if empirically and conceptu-
ally valid subscales exist. Internal consistency reliability
was assessed via Cronbach’s alpha. Correlations with the
BEHAVE-AD and Cohen-Mansﬁeld Agitation Inventory
were examined to evaluate construct validity.
RESULTS: Factor analysis resulted in identiﬁcation of 3
agree subscales (difﬁculty, attention seeking, autonomy)
and 5 cope subscales (predictability, self direction, need-
iness, job satisfaction, affect). Total scores were internally
consistent, with alphas of 0.74 for the agree scale and
0.95 for the cope scale. Internal consistency reliability
was also acceptable for the 3 agree subscales (0.69, 0.77,
0.57) and for the 5 cope subscales (0.89, 0.86, 0.83, 0.86,
0.79). The M-NCAS agree and cope total scale scores cor-
related most highly with the BEHAVE-AD aggressiveness
and anxiety/phobia subscales (r = 0.36, r = 0.35; r = 0.43,
r = 0.35 respectively: p < 0.001) and the CMAI
verbal/non-aggression and aggression subscales (r = 0.45,
r = 0.32; r = 0.34, r = 0.31, p < 0.001), indicating 
adequate construct validity.
CONCLUSIONS: The 32-item M-NCAS is an internally
consistent and valid scale for capturing both dementia-
speciﬁc behaviors and nursing perception of job burden
associated with those behaviors. The M-NCAS provides
detailed item-level as well as subscale-level data.
MENTAL HEALTH—Health Policy Presentations
PMH35
LABOR SUPPLY OF POOR RESIDENTS IN
METROPOLITAN MIAMI:THE ROLE OF
DEPRESSION AND THE CO-MORBID EFFECTS
OF DRUG USE
Alexandre PK, French M
University of Miami, Miami, FL, USA
About 1 in every 20 employees experience depression in
the U.S. A recent study estimated that in 1990 the eco-
nomic costs of depression amounted to $43 billion, with
absenteeism alone contributing $12 billion.
OBJECTIVES: The study used 1996–1997 data col-
lected in crime-ridden and low-income neighborhoods of
Miami, Florida to 1) examine the relationship between
depression and employment; 2) conditional on being
employed, estimate the effect of depression on annual
weeks worked; 3) examine the robustness of the model
estimates to the co-morbid effects of drug use.
METHODS: The labor supply measures included
employment in past 30 days and number of weeks
worked in past 12 months. The analysis estimated a 
univariate probit model of employment as well as a
bivariate probit model of depression and employment,
which accounted for the possible correlation between the
unobserved determinants of depression and employment.
The annual weeks worked speciﬁcation was estimated by
a standard Tobit and an instrumental variable Tobit
model, which, besides the censoring of the observations,
accounted for the possible endogeneity of depression.
RESULTS: Results indicate that depressed individuals
had a 0.18 lower probability of employment relative to
non-depressed individuals in the univiariate probit model
and a 0.15 lower probability in the bivariate model. Both
standard and IV Tobit models found that depression 
signiﬁcantly reduced the number of annual weeks worked
by 8 weeks. Co-morbid drug use signiﬁcantly contributed
to the estimated effects of depression.
CONCLUSIONS: Prevention and/or treatment of mental
health problems such as depression may yield economic
beneﬁts by promoting employment and enhancing labor
supply. While expansion of mental health services may be
particularly beneﬁcial to the unemployed, employers may
ﬁnd it economically efﬁcient to allocate more resources
to stress management training and job redesign.
PMH36
IMPACT OF PRIMARY PAYER TYPE ON ACCESS
TO ANTIDEPRESSANT PHARMACOTHERAPY
AMONG PATIENTS DIAGNOSED WITH
DEPRESSION
Hou X
Washington State University, Spokane, WA, USA
OBJECTIVE: This study was designed 1) to investigate
the impact of primary payer type on access to antide-
pressant pharmacotherapy among patients diagnosed
with depression; 2) to identify predictors of antidepres-
sant pharmacotherapy, prescription for an SSRI or an
SNRI, and psychotherapy among patients diagnosed with
depression.
METHOD: Data from 1999 National Ambulatory
Medical Care Survey (NAMCS) was used for this analy-
sis. Odd ratios (OR) and 95% conﬁdence intervals (CI)
were used to investigate the impact of primary payer 
type on access to antidepressant pharmacotherapy and 
to elucidate the factors predictive of receipt of anti-
depressants, an SSRI or an SNRI and psychotherapy.
Model variables included age, gender, race, payer type,
region, metropolitan status, self-report depression as a
reason for the ofﬁce-based encounter, and duration of the
encounter.
RESULTS: Among estimated 19,445,888 patients 
diagnosed with depression in 1999, 74.0% were pre-
scribed with antidepressant pharmacotherapy, 56.7%
were prescribed an SSRI or SNRI and 40.8% received
psychotherapy. Medicaid beneﬁciaries (7.8%) were 70% 
